Spinogenix, Inc.
PrivateLast Round
Seed Round
Mar 9, 2026
Total Funding Raised
$4.85M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Spinogenix, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule drugs designed to regenerate synapses and reverse declines in cognitive and motor function.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2G
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Spinogenix, Inc. Comparables
Compare Spinogenix, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gate Neurosciences | 79% | |
| PharmatrophiX | 79% | |
| PridCor Therapeutics | 79% | |
Spinogenix, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Mar 9, 2026 | ||||
| Grant | Sep 12, 2023 | ||||
| Grant | Jul 11, 2023 | ||||
| Grant | Jan 5, 2021 | ||||
| Grant | May 1, 2018 |
Spinogenix, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| U.S. Department of Defense | Grant |
| U.S. Department of War | Grant |
| National Institute on Aging | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 26, 2026
Presented at the Schizophrenia International Research Society (SIRS) 2026 Annual Congress.
- Mar 26, 2026
Early improvements reported for schizophrenia drug tazbentetol at SIRS 2026.
Spinogenix, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |